Cytokinetics Class Action Lawsuit: Shareholders in Focus

Purchasers of common stock in Cytokinetics, Inc. between December 27, 2023, and May 6, 2025, may be entitled to compensation due to allegedly false and misleading statements made by the company's defendants. The lawsuit claims that investors suffered damages after the true details of the New Drug Application (NDA) submission and approval process for aficamten entered the market.

Key Takeaways:

• The lead plaintiff deadline for the Cytokinetics class action is November 17, 2025.
• The lawsuit alleges that defendants made false and/or misleading statements regarding the timeline for the NDA submission and approval process for aficamten.
• According to the lawsuit, defendants failed to disclose material risks related to Cytokinetics' failure to submit a Risk Evaluation and Mitigation Strategy (REMS) that could delay the regulatory process.
• The Rosen Law Firm, a global investor rights law firm, is representing investors in the class action.
• The firm has a track record of success in leadership roles, with over $438 million recovered for investors in 2019 alone.
• Laurence Rosen, Esq., Philip Kim, Esq., and The Rosen Law Firm, P.A. are the attorneys handling the case.

Statistics:

• The Cytokinetics class action lawsuit has already been filed.
• The lawsuit alleges that investors suffered damages due to allegedly false and misleading statements made by the company's defendants.
• The Rosen Law Firm recovered over $438 million for investors in 2019.
• The firm has been ranked in the top 4 each year since 2013 for number of securities class action settlements.

Sources:

• Rosen Law Firm
• Law360
• ISS Securities Class Action Services
• Lawdragon
• Super Lawyers